(Q34022312)

30 July 2017

title

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

5

Youlia Kirova

1 reference

30 July 2017

Romuald Le Scodan

1

1 reference

30 July 2017

Ludivine Jouanneau

2

1 reference

30 July 2017

Christophe Massard

3

1 reference

30 July 2017

Maya Gutierrez

4

1 reference

30 July 2017

Pascal Cherel

6

1 reference

30 July 2017

Julie Gachet

7

1 reference

30 July 2017

Alain Labib

8

1 reference

30 July 2017

Emmanuelle Mouret-Fourme

9

1 reference

30 July 2017

language of work or name

English

0 references

publication date

19 September 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

page(s)

395

1 reference

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Breast cancer subtypes and survival in patients with brain metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Whole-brain radiotherapy in the management of brain metastasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

CNS metastases in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Sensitization of breast cancer cells to radiation by trastuzumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Determinants and prognoses of locoregional and distant progression in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Radiation therapy in the management of brain metastases from breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Radiosurgery for brain metastases: a score index for predicting prognosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Radiation-induced dementia in patients cured of brain metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

HER-2/neu expression in primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Brain metastases in breast cancer: prognostic factors and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Survival after brain metastases from breast cancer in the trastuzumab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-395

Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185282

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival

29 October 2018

1 reference

12 December 2020

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

1 reference

12 December 2020

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment

1 reference

12 December 2020

Risk factors for brain relapse in patients with metastatic breast cancer

1 reference

12 December 2020

A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases

1 reference

12 December 2020

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status

1 reference

12 December 2020

Extended survival in women with brain metastases from HER2 overexpressing breast cancer

1 reference

12 December 2020

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-395

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference